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Summary
Objective: We wanted to assess the effect of rapid diet-induced weight loss on the function of obese, knee osteoarthritis (OA) patients.
Methods: Eighty patients with knee OA, 89% women (nZ 71), were recruited. Mean (SD) body-mass index (BMI) was 35.9 (5.1) kg/m2 and
age 62.6 (11.1) years. Patients were randomized to either a low-energy diet (LED 3.4 MJ/day), or a control diet (5 MJ/day). The LED group had
weekly dietary sessions, whereas the control group was given a booklet describing weight loss practices. Changes in body weight and body
composition were examined as independent predictors of changes in knee OA symptoms. Symptoms were monitored by the Western Ontario
and McMaster Universities’ (WOMAC) OA index.
Results: The LED and control group lost a mean (SE) of 11.1 (0.6)% and 4.3 (0.6)%, respectively, with a mean difference being 6.8% (95%
conﬁdence interval (CI): 5.5 to 8.1%; P! 0.0001). The decrease in body fat percent was higher in the LED group, 2.2% (1.5 to 3.0%;
P! 0.0001). The total WOMAC index improved in the LED group (P! 0.0001), but not in the control group (PZ 0.12), mean difference:
219.3 mm (369.2 to 69.4 mm; PZ 0.005). The ‘Number Needed to Treat (NNT)’ to ensure an improvement in WOMAC R 50% was 3.4
(2.1 to 8.8) patients. Changes in total WOMAC index were best predicted by the reduction of body fat percent, with a 9.4% (4.8 to 13.9%)
improvement in WOMAC for each percent of body fat reduced (PZ 0.0005).
Conclusions: In our patients with knee OA, a weight reduction of 10% improved function by 28%. LED might be of advantage to control diet
because of the rapidity of weight loss and a more signiﬁcant loss of body fat.
ª 2004 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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Osteoarthritis (OA) is a major cause of morbidity and dis-
ability among the elderly, affectingeas it doeseapprox-
imately 70% of population over 65 years of age1. Knee OA
is accompanied by both pain and loss of function, both of
which are of crucial importance for social competency2.
Non-surgical therapy of knee OA often focuses on a phar-
macological approach and includes analgesic agents or
non-steroidal anti-inﬂammatory drugs (NSAIDs)3. This type
of therapy may imply serious health hazards because of
adverse gastrointestinal effects4,5. Overweight, and espe-
cially obese, persons run a high risk of OA in the knee and
probably also the hips and hands, although the mechanism
by which obesity causes OA is poorly understood6. Lifestyle
changes are gaining increasing recognition in the manage-
ment of OA, and stepping up advice on the importance of
increased physical therapy and weight reduction is increas-
ingly being recommended7. At present, there is no con-
sensus as to the beneﬁts provided by weight loss in obese
patients with knee OA8, or whether weight loss has to be in
combination with increased physical ﬁtness3. However,
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Received 23 March 2004; revision accepted 5 October 2004.2reduced body weight will be beneﬁcial for OA patients in
several ways9e14, including a reduced load on the weight-
bearing joints6,15. There is an indication that the reduction in
body fat, rather than body weight overall, may be the best
predictor for improvement of OA symptoms in the knee16.
We conducted a randomized, controlled trial to quantify
how much pain relief and increased physical function
elderly obese patients with knee OA would have, following
an intensive 8-week dietary weight loss intervention.
Methods
STUDY DESIGN AND SELECTION OF PATIENTS
After approval by the local ethical committee, patients
were recruited from the outpatient clinic of the Department
of Rheumatology, H:S Frederiksberg Hospital, Denmark.
Overweight patients over 18 years of age, with primary knee
OA, diagnosed according to the American College of
Rheumatology17 were considered eligible for the trial. All
our patients had radiographic severity grade 2 or 3 on the
Kellgren and Lawrence scale18. Major exclusion criteria
were: history or active presence of other rheumatic diseases
that might be responsible for secondary OA, and diabetes
mellitus, as well as other endocrine disorders. Likewise,
substantial abnormalities in hematological, hepatic, renal
or cardiac functions would exclude a participant from0
21Osteoarthritis and Cartilage Vol. 13, No. 1enrollment. The patients had to be overweight as deﬁned by
body-mass index (BMI)O 28 kg/m2. Only patients who ex-
plicitly expressed a clear, unequivocal motivation for weight
loss and who were ﬂuent in Danish, were invited to
participate. Before inclusion in the study, fasting blood
glucose was measured as well as hemoglobin and TSH.
The participants were asked not to change medication
during the 8-week period of the study.
TREATMENT ASSIGNMENT
All the subjects were randomly assigned to either 8 weeks
of low-energy diet (LED; 3.4 MJ/day) or an 8-week con-
ventional hypo-energetic, high protein diet (app. 5 MJ/
day)edeﬁned as a control group. For every 16 patients
included, randomization was done in a stratiﬁed way,
according to gender, BMI and ageeensuring homogeneity
between intervention groups.
The LED consisted of nutrition powder (Speasy, Dansk
Droge A/S) dissolved in water and was taken as six daily
meals, giving the patient 3.4 MJ/day. This met all the re-
commendations for a daily intake of high quality protein19;
37 energy percent (E%) from protein (soy protein) providing
the essential amino acids, 47 E% from carbohydrate,
16 E% from vegetable fat (primarily from rapeseed oil),
and ﬁbers from oat-bran (15 g/day). The LED group
received nutritional instruction and behavioral therapy, by
the same experienced dietician, at weekly sessions (1.5 h/
week) throughout the 8 weekseto reinforce and continu-
ously stimulate the patients’ decision about weight reduc-
tion, and to encourage a high degree of compliance.
Subjects receiving the conventional diet attended a thor-
ough presentation, by the same dietician who treated the
LED group, that gave nutritional advice in a 2-h session at
baseline, and recommending ordinary foods in amounts,
which would provide the patients with approximately 5 MJ/
day. After this initial tutoring, all the patients in the hypo-
energetic group received ideas for diet plans in a booklet
providing the participants with a wealth of ‘good-advice’ on
trying to reduce body weight. Thus, the patients assigned to
the conventional hypo-energetic diet, were used as a control
group, as there was no contact with the dietician after the
dietary consultation at baseline.
OUTCOME MEASURES
The changes in body weight and body composition were
examined as independent predictors of changes in the
symptoms of knee OA. At baseline and after 8 weeks inter-
vention body weights of all patients’ were measured on
a decimal scale (TANITA BWB-600S, ‘Frederiksberg
Vægtfabrik’, Copenhagen, Denmark). Body composition
was estimated by the bioimpedance method with an anim-
eter (HTS-engineering, Odense, Denmark), and fat-free
mass and fat mass were calculated with Danish standard
equations20. Dual-energy X-ray (DXA) measures were
obtained from all the patients at baseline (Norland DXA
XR-36) and used for more precise characterization21.
Symptoms of OA, as perceived by patients prior to the
assessment, were monitored by the Western Ontario and
McMaster Universities’ (WOMAC) OA index, a validated,
disease-speciﬁc questionnaire addressing the severity of
joint pain (ﬁve questions), stiffness (two questions), and
limitation of physical function (17 questions). The visual
analogue scale (VAS) version of the index was used, with
the patient assessing each question on a 100 mm VAS. The
global 3-dimensional total WOMAC index was calculated bythe summation of all 24 components, with 2400 mm being
the worst possible score22,23.
Furthermore, the index of Lequesne was applied, which
is a Likert scale that also adds a 3-dimensional approach
to the severity of the knee OA24,25. Finally, the Health
Assessment Questionnaire (HAQ) was used to investigate
the patients’ disability26.
SAMPLE SIZE AND STATISTICAL ANALYSIS
We wanted to detect a signiﬁcant effect-size (ESZ
jmI mCj/s) R 0.8, which indicates a large effect compared
to a proper placebo, whereas an ES! 0.2 is considered
small and ESO 0.5 is moderate8,27,28. An expected
ES R 0.8 seemed reasonable, at least according to the
study, based on a controlled clinical trial, by Huang et al.29
who reported results from a dietary intervention equivalent
to an ES of 1.8 (analyzed via difference in Lequesne Index)
after an arithmetic mean weight loss between groups of
9.7 kg. We set aZ 5% and with a power (1 b) of 90% and
a desired ES of 0.8, we calculated the sample size as 34
knee OA patients in each of the two groups30. For practical
reasons, 16 participants were included at a time and we
increased the sample size to 48 patients per group to allow
a dropout rate of more than one in four. If the dropout rate is
equal between the groups, and the missing data at follow-
up (8 weeks) is missing at random, the risk of making a type
I error is independent of ‘last observation carried forward’
bias31. All changes in clinical outcomes were analyzed as
the difference from baseline (X8X0), and the percentage
change from baseline (calculated from the ratio: X8/X0).
Data were analyzed using a two-factor analysis of covar-
iance, with a factor for treatment and a factor for gender,
using the baseline value as covariate to reduce the random
variation32, and increase power33. Unless stated otherwise,
results are expressed as the difference between the ﬁnal
group means and 95% conﬁdence interval (CI) with the
associated P values, based on the General Linear Model
(GLM) procedure34. To determine clinical efﬁciency, which
we based on the relief of symptoms, we calculated the
Number Needed to Treat (NNT)35,36. For the individual
participant, a clinically signiﬁcant improvement (‘treatment’)
was deﬁned as a reduction in WOMAC index R 50%;
extrapolated from the recommendations for pain meas-
ures37. To explore the best predictors of reduction in total
WOMAC index, we used a stepwise linear-regression anal-
ysis with a no-intercept statement applied, with percentage
change from baseline as response. All tests for homoge-
neity in the discrete data were analyzed using a c2-test, with
a Yates correction. The SAS statistical package (version
8; SAS Institute Inc., Cary, NC, USA) was used for all
statistical analyses.
Results
PATIENT CHARACTERISTICS
A total of 109 patients were screened prior to the
enrollment of 96 participants in the study and they were
randomly assigned to receive LED or a conventional hypo-
energetic control diet. The 13 subjects, who were not
enrolled in the study, were excluded for the following
reasons: three patients had a BMI! 28 kg/m2; two had
hypothyroidism; one patient had previously undergone
operation in both knees; seven patients decided to withdraw
their consent before randomization and without further
explanation. After the random allocation of 48 subjects to
22 R. Christensen et al.: Is weight loss the cure for knee OA?each group, four patients in the LED group and three
patients in the control group decided, before entering the
study, to withdraw without further explanation. During the
study, three patients in the LED group withdrew because of
non-compliance with the intervention-regime and one
decided to have a sub-acute knee replacement and did
not turn up for therapy. In the control group, three withdrew
due to lack of motivation, one due to a broken arm and one
was excluded due to the diagnosis of type 2 diabetes
mellitus. The following analyses are based on completers
only, because of group similarity according to the low per-
centage of dropouts in the LED and control group, 4/44
(9%) and 5/45 (11%), respectively (c2YatesZ 0.001;
PZ 0.97). Patients in the two groups had similar demo-
graphic and baseline characteristics (Table I). The average
knee OA patient completing this trial was a 60-year-old
woman, with a BMI of 36 kg/m2, representing 20 kg of
excess body weight. Patients had a moderate OA according
to WOMAC and Lequesne Index and were well functioning
apart from their knee OA as indicated by the HAQ.
WEIGHT AND BODY COMPOSITION OUTCOMES
Table II shows the outcomes after 8 weeks intervention.
There was a signiﬁcant weight reduction in both groups,
while the LED group showed a signiﬁcantly higher effect on
body weight (P! 0.0001) than the control group, with a
mean difference being 6.8 percentage points (5.5 to 8.1%)
and 6.6 kg (5.3 to 7.9 kg). The change in body composition
was more favorable in the LED than in the control group,
e.g., the percentage of body fat decreased the most after
LED, with a mean difference being 2.2 percentage points
(1.5 to 3.0%; P! 0.0001). The proportion of patients who
achieved more than 5% weight reduction in the LED andcontrol group was: 92.5% and 25%, respectively (c2YatesZ
34.9; P! 0.0001). Whereas the percentage of patients
achieving O10% weight loss was 50% and 0%, respec-
tively (c2YatesZ 24.1; P! 0.0001), which corresponds to
an NNTZ 2 (1.5 to 2.9) patients.
EFFICACY RESULTS
There was an improvement in the primary symptom
outcome measure represented by the total WOMAC index
(Table II) compared with baseline in the patients receiving
LED (P! 0.0001), whereas there was no signiﬁcant effect
after the control diet (PZ 0.12) with a signiﬁcant difference
between the ﬁnal group means, ESZ 0.65 [0.20 to 1.10]
(PZ 0.005). The group receiving LED showed a highly
signiﬁcant improvement in the WOMAC-assessed function-
score (P! 0.0001). There was no corresponding improve-
ment in this score for those on the control diet (PZ 0.10).
Thus, LED resulted in a signiﬁcant improvement in the
WOMAC-assessed function-score compared to the reduc-
tion produced by the control diet, ESZ 0.69 [0.24 to 1.14]
(PZ 0.003). There was a signiﬁcant improvement in
the WOMAC-assessed pain-score within the LED group
(PZ 0.001), whereas no effect was seen after the control
diet (PZ 0.10). However, this difference was of no signiﬁ-
cance when the groups were compared after the interven-
tion (ESZ 0.33 [0.11 to 0.77]; PZ 0.15). Likewise, there
was a signiﬁcant improvement in the WOMAC-assessed
stiffness-score within the LED group (PZ 0.002), whereas
no effect was seen after the control diet (PZ 0.17) and with
no difference between the groups (ESZ 0.36 [0.08 to
0.80], PZ 0.11). The Lequesne Index showed no signiﬁ-
cant effect of the intervention, neither within the LED group
(PZ 0.06) nor between the groups (ESZ 0.12 [0.32 to
0.56]; PZ 0.59).Table I
Baseline characteristics of participants by randomization group
Characteristics Mean (SD)
Low-energy diet
(nIZ 40;
3.4 MJ/day)
Control
(nCZ 40;
app. 5 MJ/day)
Total (nZ 80; range)
Women, no. (%) 35 (88%) 36 (90%) 71 (89%)
Age (years) 60.5 (11.6) 64.6 (10.4) 62.6 (11.1) (35 to 90)
Body-mass index (kg/m2) 36.3 (5.6) 35.5 (4.6) 35.9 (5.1) (28.8 to 55.1)
Weight (kg) 96.4 (15.5) 97.1 (13.4) 96.8 (14.4) (66.4 to 142.8)
Lean body mass (kg)y 43.9 (10.4) 43.3 (8.3) 43.6 (9.4) (30.0 to 70.3)
Fat mass (kg)y 47.6 (11.9) 49.7 (10.2) 48.6 (11.1) (27.6 to 85.3)
Bone mineral content (kg)y 2.867 (0.402) 2.985 (0.389) 2.926 (0.398) (2.284 to 3.998)
Fat (%)y 50.4 (8.0) 51.7 (6.4) 51.0 (7.2) (27.3 to 63.3)
Bone mineral density (g/cm2)y 1.054 (0.110) 1.096 (0.166) 1.075 (0.141) (0.878 to1.804)
Fat-free mass (kg)z 50.6 (9.0) 51.1 (8.3) 50.9 (8.6) (34.0 to 76.7)
Plasma glucose (mmol/L) 5.9 (1.1) 5.8 (0.7) 5.8 (0.9) (4.3 to 10.2)
C-reactive protein (mg/L)x 3.8 (2.4; 6.5) 3.4 (2.1; 7.9) 3.5 (2.1; 7.2) (0.5 to 27.5)
Health assessment questionnaire, scorex 0.4 (0.2; 0.9) 0.4 (0.2; 0.6) 0.4 (0.2; 0.8) (0 to 1.8)
Lequesne Index, total (score) 12.7 (4.3) 12.7 (4.4) 12.7 (4.3) (0 to 21)
WOMAC indexk
Total index (mm) 950.1 (455.8) 838.2 (546.8) 894.1 (503.3) (0 to 2101)
Pain (mm) 197.0 (96.0) 170.5 (115.7) 183.7 (106.5) (0 to 469)
Function (mm) 678.9 (338.0) 592.1 (399.8) 635.5 (370.4) (0 to 1440)
Stiffness (mm) 74.5 (50.0) 75.1 (55.2) 74.8 (52.3) (0 to 189)
yAssessed using Dual-energy X-ray (Norland DXA XR-36).
zAssessed using bioimpedance (HTS-engineering, Odense, Denmark), signiﬁcantly different from the sum of lean body mass and bone
mineral content 4.4 kg (95% CI: 3.6 to 5.1 kg; P! 0.0001).
xShowed a non-gaussian distribution, thus, presented as median (interquartile range).
kSum of visual analogue scale scores.
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Change in outcomes from baseline after 8 weeks in knee OA patients who completed either the intensive low-energy diet (Speasy) or
a conventional dietetic regime (Control)
Characteristics Mean (SE) Difference
(95% CI)
P value
Low-energy diet
(nIZ 40; 3.4 MJ/day)
Control
(nCZ 40; app. 5 MJ/day)
Weight loss (%) 11.1 (0.6) 4.3 (0.6) 6.8 (5.5 to 8.1) !0.0001
DWeight (kg) 11.0 (0.6) 4.4 (0.6) 6.6 (7.9 to 5.3) !0.0001
DFat-free mass (kg)y 3.0 (0.4) 1.2 (0.4) 1.8 (2.4 to e1.1) !0.0001
DFat mass (kg)y 7.7 (0.5) 2.9 (0.5) 4.8 (5.9 to 3.8) !0.0001
DFat (%)y 3.3 (0.3) 1.0 (0.4) 2.2 (3.0 to 1.5) !0.0001
DLequesne Index, total (score) 1.4 (0.8) 1.0 (0.8) 0.4 (2.1 to 1.2) 0.59
Change in WOMAC indexz
DTotal index (mm)x 334.5 (69.1) 115.2 (72.4) 219.3 (369.2 to 69.4) 0.005
DPain (mm)x 57.0 (16.9) 29.8 (17.7) 27.2 (64.0 to 9.7) 0.15
DFunction (mm)x 252.5 (49.6) 85.6 (51.9) 166.9 (274.5 to 59.3) 0.003
DStiffness (mm)x 22.6 (7.2) 10.2 (7.4) 12.4 (27.7 to 2.8) 0.11
yAssessed using bioimpedance (HTS-engineering, Odense, Denmark).
zSum of visual analogue scale scores.
xTwo patients in the control group did not provide answers for the WOMAC questionnaire after 8 weeks (nCZ 38).Based on those subjects, who showed more than 50%
reduction in the total WOMAC index after LED compared to
the control diet, the NNT was 3.4 (95% CI: 2.1 to 8.8). Thus,
more than 25% of obese patients with knee OA will ex-
perience a clinically signiﬁcant improvement in daily func-
tional activities after an 8-week period with LED.
When testing to what extent the individual changes
in body composition (and body weight) could predict
%changes in total WOMAC index, the best predictor was
the change in the percentage of body fat (PZ 0.0001).
The change in body fat (expressed as percentage
points) explained as much as 18% of the variation in
%WOMAC (R2Z 0.179; PZ 0.0001); with an effect-slope,
bZ 9.4%WOMAC per body-fat percentage point (95%
CI: 4.8 to 13.9%WOMAC per body-fat percentage point);
Fig. 1(a). In comparison, the %reduction in body weight
predicted 15% of the variation in %WOMAC (R2Z 0.146;
PZ 0.0005); with an effect-slope, bZ 2.8%WOMAC per
%body-weight (95% CI: 1.3 to 4.3%WOMAC per %body-
weight); Fig. 1(b). When analyzing %changes in total
WOMAC index in a multivariate regression analysis model,
using the change in body fat (percentage point) and
%weight loss as independent predictors, neither of the
variables stays below the predeﬁned signiﬁcance level
(aZ 0.05), PO 0.07; and the model does not add more
information about the variability (R2Z 0.180).
Discussion
The present study demonstrates that a highly signiﬁcant
increase in the function of obese patients with knee OA may
be obtained by an intervention consisting of simple weight
reduction. The typical patient in our clinic is an elderly
woman, signiﬁcantly overweight, and trapped in a negative
pattern of continual weight gains and pain, accompanied in
turn, by decreasing activity and functional capacity.
We, like others, have conducted rather extensive training
programs with elderly, knee OA patients38 and during these
activities it has been our deﬁnite impression that obesity
has been a key factor behind the troubles of this group.
While training in principle is good, it will increase the wear-
and-tear of the diseased joint and some indications ofadverse effects of training have been found38. Likewise,
reduction of pain may in some cases lead to accelerated
joint destruction, although this tends to be more pronounced
with the use of certain NSAIDs39,40. By contrast, a weight
reduction would not be expected to induce any untoward
effect for the patient, provided the intervention ensures
a sufﬁcient supplement of vitamins and essential
nutrients19,41. In our study, this was accomplished by
employing a highly enriched dietary supplement42, which
enabled the patients to lose an optimum of 1.5 kg per week.
Epidemiological evidence strongly supports the notion of
excess weight being an important factor in the development
of knee OA, with a decrease in risk of 50% after a reduction
in BMI of more than 2 units (app. 5.1 kg) over a period of 10
years15; it is quite logical to assume that weight loss will
be of beneﬁt to patients with OA43,44. Our results seem
to conﬁrm indications of such an effect of weight loss
in OA16,29,44e48.
We found a highly signiﬁcant association between
increase in function and the reduction in the percentage
of body fat, as 18% of the variation in the total WOMAC
index change could be explained by the reduction in the
percentage of body fat, with a change of 9.4%WOMAC per
%body-fat. The weight loss alone predicted 15% of the
variation, with a change of 2.8%WOMAC per %body-
weight. These results are in accordance with a preliminary
observation of body composition being a better predictor of
change in the symptoms of knee OA, than body weight
itself16. In rough ﬁgures, our results indicated that a 10%
weight reduction would result in 28% decline in knee OA
trouble. A moderate weight loss of 10% has important
implications for obese persons in general10,13. In the
present study the NNT (based on a 10% weight loss
criterion) was 2 (95% CI: 1.5 to 2.9), whereas the NNT
calculated on the basis of R 50% reduction in total
WOMAC was four patients.
The western world faces an obesity problem of vast
dimensions. Obesity and diabetes are major causes of
morbidity and mortality in the United States49,50, as in the
rest of the world. Body weight increases with age up to
about 60 and then levels off51. At present, there is no
consensus on the subject of elderly and ideal body weight
and its association with mortality and morbidity52. However,
24 R. Christensen et al.: Is weight loss the cure for knee OA?based on the cross-sectional and cohort studies published,
it seems reasonable to assume that weight loss in obese
elderly people can reduce morbidity from diabetes and car-
diovascular diseases51,53. In the case of type 2 diabetes, a
reduction of the incidence may be obtained by the recom-
mendation of a daily physical activity level (PAL) above
1.854. ‘The Finnish Diabetes Prevention Study’ randomized
522 overweight subjects with impaired glucose tolerance to
either lifestyle intervention or a control group. They found
that applying counseling in both weight reduction (3.5 kg
after 2 years) and increased physical activity in high-risk
subjects, reduced the risk of diabetes by 58% at follow-up
after 3.2 years55,56. If we combine the quantity of weight lost
in this study, with the observed increment in physical
function and ability for the majority of these patients, it may
be speculated that their PAL was increased as well.
Overweight knee OA patients’ insulin levels are statisti-
cally higher than in matched obese subjects without OA57.
The insulin level (and insulin resistance) is the factor most
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Fig. 1. Scatter plot showing the individual patients expressed as
percentage change in total WOMAC index from baseline, following
a weight loss regime, nZ 78 patients. a: Reduction in total
WOMAC index vs the reduction in body fat (%point). With a highly
signiﬁcant effect-slope, bZ 9.4%WOMAC per body fat %point
(95% CI: 4.8 to 13.9; PZ 0.0001). b: Reduction in total WOMAC
index vs the percent reduction in body weight, bZ 2.8%WOMAC
per %weight reduction (95% CI: 1.3 to 4.3; PZ 0.0005).strongly associated with diabetes incidence58,59 and con-
version to a healthier lifestyle may prevent the majority of
new cases of type 2 diabetes60.
Our results were obtained after a rather short intervention
of 8 weeks, which lies well within the waiting-list interval for
a knee operation in our district. An improvement in function
due to weight loss is of interest for many patients and might
be regarded as an alternative to knee replacement.
Bachmeier et al. studied the outcomes in elderly OA
patients undergoing total hip (nZ 86) or knee (nZ 108)
replacementethe ﬁrst year after surgery61. Based on their 3
month-results, we extracted and calculated the arithmetic
mean %change in total WOMAC index and found a 36%
reduction. In comparison, based on the mean values
(presented in Tables I and II), our results show a reduction
in total WOMAC index equivalent to 35% after 8 weeks
intervention with LED. With equipotent results, weight loss
might be advocated in the case of obese patients before
a knee replacement is considered. The possible inﬂuence
on the decision whether to operate or not may depend on
many factors and should be tested in a controlled setting.
The patients had a 1-h personal interview with the
dietician before and after the 8-week period of once-weekly
team therapy, i.e., the total time spent per patient was 3.5 h.
Add to this the daily cost of about 10 US dollars, which is
the average price of Speasy LED nutrition powder. Taken
over 56 days, as a substitute for all other meals, the total
cost for the outpatient clinic will thus be far less than 1000
US dollars for the entire 8-week period, which is consider-
ably cheaper than most other treatment alternatives in
OA62. The number of visits in the intervention group was
high compared with the control group. The effect of
attention in this group of patients will have to be taken into
account; however, the considerable weight reduction in the
intervention group could not have been obtained without the
support of the dietician or the other participants in the group.
Our control group had a trend towards an effect on pain just
by entering the study. While not being of signiﬁcance
per se, this effect meant that the difference in the inter-
vention group could only be shown in comparison with
baseline and not as a treatment effect. This might be due to
a type II error, as an ESZ 0.3 would require 176 patients in
each group, with a statistical power (1 b) of 80%, to detect
a signiﬁcant difference (aZ 5%) between the two groups30.
The present 8 week intervention cannot go it alone, and
the program must include a follow-up to stabilize weight. A
general dogma among laymen and professionals is that
rapid weight loss will result in a bad long-term maintenance.
However, the lesson from obesity management programs
shows that greater initial weight loss is associated with
better long-term prognoses63,64. It is evident that substantial
weight loss results in a reduced resting metabolic rate
(RMR)65, and that formerly obese subjects had a 3e5%
lower mean relative RMR than control subjects66. However,
there is no evidence to suggest that the rate of weight loss
achieved by very LEDs is associated with any detriment to
body composition or metabolic rate67. Accordingly, obese
(knee OA) individuals should not let undue concerns about
the hazards of weight cycling deter them from efforts to
control their body weight68. As a further motivating factor,
the increase in function of our patients with knee OA is very
valuable and has a high impact on the health-related quality
of life48. It is not known exactly how much functional
impairment in these patients is due to overweight as
compared with the joint disease per se. However, with the
limited possibilities of medical therapy of the joint, the most
effective non-surgical intervention is diet, both with regard
25Osteoarthritis and Cartilage Vol. 13, No. 1to increase in function and rapidity of the result. In com-
parison, the symptom relief in knee OA patients, associated
with taking glucosamine sulfate for 3 years, is only 24%69.
In conclusion, we found that an 8-week program with
a 10% weight loss gave a highly signiﬁcant increase in
function in obese patients with knee OA. As the patients
show a corresponding reduction in their risk of other health
problems as well, weight loss is proposed as a ﬁrst-choice
therapy for knee OA.
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